Profile data is unavailable for this security.
About the company
Zhejiang Starry Pharmaceutical Co., Ltd. is principally engaged in the research and development (R&D), production and sales of X-ray contrast medium, quinolone antimicrobial agents and other drugs' pharmaceutical raw materials and intermediates. The X-ray contrast medium's major product is iohexol active pharmaceutical ingredient. Quinolone antimicrobial agents' major products are levofloxacin hydrochloride active pharmaceutical ingredient and levofloxacin hemihydrates active pharmaceutical ingredient.
- Revenue in CNY (TTM)2.27bn
- Net income in CNY46.95m
- Incorporated1997
- Employees1.85k
- LocationZhejiang Starry Pharmaceutical Co LtdXianjuTAIZHOU 317300ChinaCHN
- Phone+86 57 687718605
- Fax+86 57 687718686
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tibet Weixinkang Medicine Co Ltd | 1.29bn | 248.69m | 4.10bn | 701.00 | 16.48 | 2.86 | -- | 3.18 | 0.5715 | 0.5715 | 2.96 | 3.30 | 0.7114 | 18.19 | 5.88 | 1,840,383.00 | 13.71 | 8.20 | 17.78 | 11.13 | 50.81 | 50.20 | 19.28 | 11.53 | 3.10 | -- | 0.0045 | 59.11 | -5.43 | 12.13 | 20.94 | 23.85 | -5.61 | 38.96 |
| Hunan Warrant Pharmaceutical Co Ltd | 1.45bn | 222.11m | 4.11bn | 1.16k | 18.50 | 2.30 | -- | 2.84 | 2.37 | 2.37 | 15.44 | 19.01 | 0.6713 | 1.50 | 8.93 | 1,246,491.00 | 9.31 | 11.21 | 11.21 | 14.05 | 64.09 | 69.00 | 13.88 | 13.96 | 3.02 | -- | 0.0252 | 8.05 | 10.84 | 18.50 | 15.60 | 19.02 | 24.49 | -- |
| Shanghai OPM Biosciences Co Ltd | 254.91m | 49.43m | 4.14bn | 285.00 | 84.07 | 1.92 | -- | 16.25 | 0.4294 | 0.4294 | 2.22 | 18.80 | 0.1095 | 2.07 | 2.54 | 894,431.90 | 2.09 | 4.34 | 2.16 | 4.65 | 58.86 | 58.31 | 19.06 | 23.40 | 19.91 | -- | 0.0315 | 45.38 | -17.41 | 48.34 | -48.72 | -- | 6.09 | -- |
| Zhejiang Starry Pharmaceutical Co Ltd | 2.27bn | 46.95m | 4.19bn | 1.85k | 89.47 | 2.38 | -- | 1.84 | 0.1368 | 0.1368 | 6.63 | 5.15 | 0.4179 | 1.98 | 5.09 | 1,231,642.00 | 0.8789 | 3.30 | 1.80 | 5.97 | 23.86 | 32.35 | 2.10 | 8.21 | 0.4121 | 1.44 | 0.6405 | 53.08 | 3.04 | 19.78 | 158.32 | -13.94 | 10.39 | -- |
| Sinotherapeutics Inc | 368.86m | 76.25m | 4.26bn | 260.00 | 55.83 | 3.54 | -- | 11.54 | 0.1682 | 0.1682 | 0.8137 | 2.65 | 0.275 | 3.08 | 5.83 | 1,418,710.00 | 5.69 | -- | 6.09 | -- | 51.77 | -- | 20.67 | -- | 9.09 | -- | 0.00006 | -- | 21.13 | -- | -34.29 | -- | -- | -- |
| Jiangsu Bioperfectus Technologies Co Ltd | 400.25m | -314.32m | 4.28bn | 684.00 | -- | 1.24 | -- | 10.70 | -5.36 | -5.36 | 6.83 | 58.77 | 0.0915 | 0.8592 | 1.57 | 585,153.50 | -7.19 | 25.41 | -8.36 | 31.26 | 63.20 | 63.37 | -78.53 | 32.86 | 6.05 | -- | 0.086 | 30.54 | -92.72 | 11.81 | -120.45 | -- | 2.43 | -- |
| Jinyao Pharmaceutical Co Ltd | 3.66bn | 107.59m | 4.44bn | 2.68k | 41.25 | 1.47 | -- | 1.21 | 0.0984 | 0.0984 | 3.35 | 2.76 | 0.5738 | 2.28 | 9.37 | 1,365,219.00 | 2.33 | 1.91 | 4.17 | 3.40 | 42.61 | 46.33 | 4.06 | 3.31 | 0.7584 | 27.18 | 0.2064 | 44.40 | 2.55 | 9.28 | 230.60 | -4.22 | -9.58 | 9.21 |
| Assure Tech Hangzhou Co Ltd | 511.29m | 160.91m | 4.47bn | 791.00 | 27.76 | 0.8625 | -- | 8.74 | 1.27 | 1.27 | 4.02 | 40.75 | 0.0799 | 1.52 | 2.67 | 646,379.60 | 2.51 | 31.83 | 2.94 | 38.97 | 38.56 | 65.82 | 31.47 | 47.86 | 8.26 | -- | 0.0166 | 16.05 | -91.84 | 25.18 | -95.35 | 33.51 | 78.77 | -- |
Data as of May 17 2024. Currency figures normalised to Zhejiang Starry Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
6.90%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Rongtong Fund Management Co., Ltd.as of 30 Sep 2022 | 5.25m | 1.53% |
| Caitong Securities Asset Management Co., Ltd.as of 30 Jun 2023 | 3.50m | 1.02% |
| Wanjia Asset Management Co., Ltd.as of 30 Jun 2023 | 2.87m | 0.84% |
| Galaxy Asset Management Co., Ltd.as of 30 Jun 2023 | 2.39m | 0.70% |
| Bank of Communications Schroder Fund Management Co., Ltd.as of 30 Jun 2023 | 2.26m | 0.66% |
| China Resources SZITIC Trust Co., Ltd.as of 30 Sep 2022 | 1.76m | 0.51% |
| Yinhua Fund Management Co., Ltd.as of 30 Jun 2023 | 1.72m | 0.50% |
| Essence Fund Co., Ltd.as of 30 Jun 2023 | 1.39m | 0.41% |
| Tebon Fund Management Co. Ltd.as of 30 Jun 2023 | 1.36m | 0.40% |
| Hwabao WP Fund Management Co., Ltd.as of 30 Jun 2023 | 1.12m | 0.33% |
More ▼
Data from 30 Jun 2023 - 30 Sep 2023Source: FactSet Research Systems Inc.
